FERG vs IDXX vs ZOMDF Stock Comparison

Ferguson Enterprises, Idexx Laboratories and Zomedica Prices as of Nov 13, 2026 Peers: Industry group
ZOMDF Zomedica Corp.
$0.10 +11.1% 1M +11.1% 1Y
Market cap
$92.51M
P/E
–
Revenue (TTM)
$38.68M
Div. yield
–
Animal Health Healthcare
3 wins

Head to Head

11 decided of 12

Idexx Laboratories leads on 4 of the 12 questions below (Idexx Laboratories 4, Ferguson Enterprises 4, Zomedica 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionFERGIDXXZOMDFLeader
Larger companyMarket capitalisation $49.17B $55.34B $92.51M IDXX
Cheaper on earningsLower P/E, profitable companies only 24.2x 46.8x -5.8x FERG
Cheaper on forward earningsLower price / next fiscal year consensus EPS 23.8x 44.6x — FERG
Faster revenue growthRevenue growth, trailing twelve months +5.2% +11.9% +31.3% ZOMDF
More profitableNet margin, trailing twelve months 6.5% 25.4% -41.4% IDXX
Better return on capitalReturn on invested capital 21.7% 45.4% — IDXX
Less leveragedLower net debt / EBITDA 1.0x 0.4x — IDXX
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +5.5% +0.4% +11.1% ZOMDF
Better 5-year returnAnnualised price return, 5 years +10.0%/yr +2.3%/yr -28.6%/yr FERG
Less volatileAnnualised volatility, 1 year 32.5% 36.2% 100.4% FERG
Higher overall scoreMean of the five percentile scores vs peers 62/100 76/100 76/100 ZOMDF

Percentile Scorecard

FERGIDXXZOMDF

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisFERGIDXXZOMDF
Valuation 30 #33 of 47 74 #175 of 660 77 #153 of 660
Growth 68 #13 of 39 70 #184 of 619 80 #125 of 619
Profitability 88 #6 of 42 98 #12 of 595 75 #150 of 595
Financial Health 55 #23 of 50 46 #371 of 683 74 #178 of 683
Shareholder Returns 69 #12 of 36 94 #30 of 459 –
Overall 62 76 76
  • FERG ranked among 50 companies in Distribution and Rental
  • IDXX ranked among 695 companies in Pharmaceuticals and Biotechnology
  • ZOMDF ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodFERGIDXXZOMDFSPY
1 month +15.0%+33.1%+11.1% -2.0%
3 months +4.7%+27.8%+25.0% -2.8%
6 months +14.6%+33.2%0.0% +2.0%
Year to date +15.2%+4.1%0.0% +10.6%
1 year +5.5%+0.4%+11.1% +12.2%
3 years +55.7%+55.0%-41.2% +68.1%
3 years, per year +15.9%+15.7%-16.2% +18.9%
5 years +60.9%+12.1%-81.5% +61.4%
5 years, per year +10.0%+2.3%-28.6% +10.1%
10 years +343.9%+545.1%— +248.5%
10 years, per year +16.1%+20.5%— +13.3%

Risk

MeasureFERGIDXXZOMDFSPY
Volatility, 1Y 32.5%36.2%100.4% 13.6%
Downside volatility, 1Y 31.7%32.6%161.5% 13.9%
Beta vs S&P 500, 1Y 1.210.840.10 1.00
Return / volatility, 1Y 0.170.010.11 0.90
Max drawdown, 5Y -43.6%-50.9%-94.0% -25.4%
From 52-week high -4.2%-8.1%-33.3% -3.2%
52-week high $267.71$766.68$0.15 $779.14
52-week low $214.24$504.70$0.07 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleFERGIDXXZOMDF
P/E now vs peer median 24.6xmedian 24.5x 47.0xmedian 17.0x -6.1xmedian 17.0x
P/S now vs peer median 1.6xmedian 1.1x 11.9xmedian 8.4x 2.5xmedian 8.4x
EV/EBITDA now vs peer median 16.6xmedian 12.9x 33.7xmedian 14.6x -5.7xmedian 14.6x
P/FCF now vs peer median 22.0xmedian 19.5x 42.6xmedian 19.0x -8.2xmedian 19.0x
P/B now vs peer median 8.5xmedian 2.4x 29.7xmedian 2.0x 0.9xmedian 2.0x
PEG now vs peer median —median 2.23 3.10median 0.43 2.65median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsFERGIDXXZOMDF
Revenue $31.35B $4.66B $38.68M
Gross profit $9.73B $2.92B $24.74M
Operating income $2.82B $1.51B -$17.57M
Net income $2.03B $1.18B -$16.00M
Free cash flow $2.26B $1.30B -$11.92M
R&D – $266.87M $5.07M
EPS (diluted) $10.42 $14.96 $-0.02
Cash & equivalents $820.00M $197.54M $7.28M
Total debt $4.13B $848.88M –
Shares (diluted) 194.80M 79.05M 979.95M
Enterprise value $46.38B $54.56B -$92.52M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricFERGIDXXZOMDF
P/E 24.6x 47.0x -6.1x
P/FCF 22.0x 42.6x -8.2x
P/Operating cash flow 19.0x 39.1x -8.5x
P/S 1.6x 11.9x 2.5x
P/B 8.5x 29.7x 0.9x
P/Tangible book 9.5x 31.7x 1.4x
EV/EBITDA 16.6x 33.7x -5.7x
EV/EBIT 18.9x 37.3x -3.3x
EV/Revenue 1.7x 12.0x 1.5x
EV/FCF 23.5x 43.1x -4.9x
EV/Operating cash flow 20.3x 39.6x -5.0x
PEG (3Y EPS CAGR) – 3.10 2.65

Growth

14 metrics
MetricFERGIDXXZOMDF
Revenue growth (1Y) 5.2% 11.9% 31.3%
Revenue CAGR (3Y) – 9.1% 17.2%
Gross profit growth (1Y) 7.5% 13.7% 23.3%
Gross profit CAGR (3Y) – 10.8% 14.6%
Operating income growth (1Y) 17.6% 15.3% 79.9%
Operating income CAGR (3Y) – 11.8% 11.5%
Net income growth (1Y) 31.6% 15.1% 81.1%
Net income CAGR (3Y) – 12.8% -2.3%
EPS growth (1Y) 34.4% 17.4% 81.1%
EPS CAGR (3Y) – 15.1% -2.3%
Operating cash flow growth (1Y) 35.9% 30.4% 46.1%
Operating cash flow CAGR (3Y) – 19.6% 4.9%
Free cash flow growth (1Y) 42.8% 35.3% 46.6%
Free cash flow CAGR (3Y) – 24.2% 20.1%

Profitability

14 metrics
MetricFERGIDXXZOMDF
Gross margin 31.0% 62.7% 64.0%
EBITDA margin 10.2% 35.7% -26.1%
Operating margin 9.0% 32.3% -45.4%
Pretax margin 8.3% 31.7% -41.7%
Net margin 6.5% 25.4% -41.4%
FCF margin 7.2% 28.0% -30.8%
Operating cash flow margin 8.3% 30.4% -29.7%
Return on equity 34.0% 67.9% -15.1%
Return on assets 11.4% 33.1% -13.7%
Return on invested capital 21.7% 45.4% –
Return on capital employed 23.4% 65.2% -16.3%
Asset turnover 1.8x 1.3x 0.3x
Cash conversion (OCF / net income) 1.3x 1.2x 0.7x
Stock comp / revenue 0.3% 1.4% 3.6%

Financial Health

11 metrics
MetricFERGIDXXZOMDF
Debt / assets 23.2% 22.9% –
Debt / equity 0.7x 0.5x –
Net debt / EBITDA 1.0x 0.4x –
Debt / FCF 1.8x 0.7x –
Liabilities / assets 67.0% 49.6% 9.3%
Equity / assets 33.0% 50.4% 90.7%
Interest coverage – 43.5x –
Current ratio 1.8x 1.2x 6.1x
Quick ratio 0.8x 0.7x 5.2x
Cash ratio 0.1x 0.2x 4.4x
Altman Z-score 5.68 23.56 2.00

Shareholder Returns

7 metrics
MetricFERGIDXXZOMDF
Dividend yield 1.4% – –
Net buyback yield 1.7% 1.7% –
Shareholder yield 3.1% 1.7% –
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusFERGIDXXZOMDF
Forward P/E 23.8xFY2026 44.6xFY2026 –
EPS, next fiscal year $10.79FY2026 $15.78FY2026 $-0.03FY2026
EPS growth, next FY +8.6%FY2026 +20.6%FY2026 –
EPS growth, the year after +19.9% +12.3% –
Revenue, next fiscal year $34.69BFY2026 $5.03BFY2026 $46.29MFY2026
Revenue growth, next FY +12.8%FY2026 +17.0%FY2026 +44.5%FY2026
Revenue growth, the year after -0.4% +0.4% +31.6%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersFERGIDXXZOMDF
Held by institutions 96.3% 93.6% 0.0%
Institutions holding 940 1,292 6
Change in shares held, QoQ +2.1% +4.1% -98.8%
Institutions buying 479 590 2
Institutions selling 344 496 0
Buyers to sellers 1.39 1.19 –

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

FERGIDXXZOMDF
FERG 1.00 0.38 -0.01
IDXX 0.38 1.00 0.05
ZOMDF -0.01 0.05 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, FERG, IDXX and ZOMDF?

Idexx Laboratories (IDXX) is the largest by market capitalisation: Ferguson Enterprises (FERG) $49.17B, Idexx Laboratories (IDXX) $55.34B, Zomedica (ZOMDF) $92.51M.

Which stock is cheaper, FERG, IDXX and ZOMDF?

Ferguson Enterprises (FERG) trades on the lowest price-to-earnings ratio (Ferguson Enterprises (FERG) 24.2x, Idexx Laboratories (IDXX) 46.8x, Zomedica (ZOMDF) -5.8x). On next year's consensus earnings, Ferguson Enterprises (FERG) is cheapest (Ferguson Enterprises (FERG) 23.8x, Idexx Laboratories (IDXX) 44.6x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Zomedica (ZOMDF) grew revenue fastest over the trailing twelve months: Ferguson Enterprises (FERG) +5.2%, Idexx Laboratories (IDXX) +11.9%, Zomedica (ZOMDF) +31.3%.

Which company is more profitable?

Idexx Laboratories (IDXX) has the highest net margin (Ferguson Enterprises (FERG) 6.5%, Idexx Laboratories (IDXX) 25.4%, Zomedica (ZOMDF) -41.4%). On return on invested capital, Idexx Laboratories (IDXX) leads (Ferguson Enterprises (FERG) 21.7%, Idexx Laboratories (IDXX) 45.4%).

Which stock has performed better?

Over the past year Zomedica (ZOMDF) returned the most: Ferguson Enterprises (FERG) +5.5%, Idexx Laboratories (IDXX) +0.4%, Zomedica (ZOMDF) +11.1%. Over five years, Ferguson Enterprises (FERG) compounded fastest (Ferguson Enterprises (FERG) +10.0%/yr, Idexx Laboratories (IDXX) +2.3%/yr, Zomedica (ZOMDF) -28.6%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Ferguson Enterprises (FERG) has been the steadiest (Ferguson Enterprises (FERG) 32.5%, Idexx Laboratories (IDXX) 36.2%, Zomedica (ZOMDF) 100.4%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, FERG, IDXX and ZOMDF?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Idexx Laboratories (IDXX) leads on 4. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.